Drug Profile


Alternative Names: CV-MG-01; Myasterix

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CuraVac
  • Class Peptides
  • Mechanism of Action Acetylcholine modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Myasthenia gravis

Most Recent Events

  • 30 May 2018 CuraVac withdraws a phase II/III trial prior to enrolment for Myasthenia gravis in Belgium and Netherlands (SC) (NCT03165435)
  • 23 Jun 2017 Phase-II/III clinical trials in Myasthenia gravis in Belgium, Netherlands (SC) (NCT03165435)
  • 29 May 2017 CuraVac plans a phase II/III trial for Myasthenia gravis in Belgium and Netherlands (NCT03165435)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top